Langenhoff B S, Oyen W J G, Jager G J, Strijk S P, Wobbes Th, Corstens F H M, Ruers T J M
Department of Surgery, University Medical Center Nijmegen, Nijmegen, the Netherlands.
J Clin Oncol. 2002 Nov 15;20(22):4453-8. doi: 10.1200/JCO.2002.12.134.
The aims of this prospective study were to investigate the potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in determining the efficacy of the local tumor ablative process and to determine the added value of FDG-PET in the detection of tumor recurrence during follow-up.
Twenty-three patients with unresectable colorectal liver metastases were followed up after local ablative therapy consisting of a standard protocol including FDG-PET scanning, computed tomography (CT) scanning, and carcinoembryonic antigen measurements. The mean follow-up period was 16 months (range, 10 to 21 months).
Ninety-six lesions was treated, 56 by local ablative treatment. Within 3 weeks after local ablative treatment, 51 lesions became photopenic on FDG-PET, while five lesions (in five patients) showed persistent activity on FDG-PET. In four of five FDG-PET-positive lesions, a local recurrence developed during follow-up; one FDG-PET-positive lesion turned out to be an abscess. None of the FDG-PET-negative lesions developed a local recurrence during a mean follow-up period of 16 months. During follow-up, 11 patients showed recurrence in the liver outside of the treated area. In all cases, previously negative FDG-PET scans became positive. Extrahepatic recurrence was encountered in nine patients during follow-up; FDG-PET showed all nine cases of tumor recurrence. There was one false-positive FDG-PET caused by an intra-abdominal abscess. In all patients, the time point of detection of recurrence by FDG-PET was considerably earlier than the detection by CT.
FDG-PET seems to have a significant impact in measuring treatment efficacy directly after local ablative therapy. Furthermore, FDG-PET has an added value in patient follow-up because it reveals recurrences earlier than conventional diagnostic modalities.
本前瞻性研究旨在探讨氟-18-脱氧葡萄糖(FDG)正电子发射断层扫描(PET)在确定局部肿瘤消融治疗疗效中的潜在作用,并确定FDG-PET在随访期间检测肿瘤复发方面的附加价值。
23例不可切除的结直肠癌肝转移患者在接受包括FDG-PET扫描、计算机断层扫描(CT)和癌胚抗原测量的标准方案局部消融治疗后进行随访。平均随访期为16个月(范围10至21个月)。
共治疗96个病灶,其中56个接受局部消融治疗。局部消融治疗后3周内,51个病灶在FDG-PET上变为放射性缺损,而5个病灶(5例患者)在FDG-PET上显示持续活性。在5个FDG-PET阳性病灶中的4个,随访期间出现局部复发;1个FDG-PET阳性病灶结果为脓肿。在平均16个月的随访期内,FDG-PET阴性病灶均未出现局部复发。随访期间,11例患者在治疗区域外的肝脏出现复发。在所有病例中,先前FDG-PET扫描阴性者均变为阳性。随访期间9例患者出现肝外复发;FDG-PET显示了所有9例肿瘤复发情况。有1例假阳性FDG-PET结果由腹腔内脓肿所致。在所有患者中,FDG-PET检测到复发的时间点比CT检测到的时间点要早得多。
FDG-PET似乎对局部消融治疗后直接评估治疗疗效有显著影响。此外,FDG-PET在患者随访中具有附加价值,因为它比传统诊断方法能更早地发现复发。